Vlad Vitoc, MD, MBA; CEO & Chairman of MAIA Biotechnology, was a guest on Benzinga’s All Access.<br /><br />MAIA is a targeted therapy immuno-oncology company focused on developing and commercializing drugs targeting cancers with novel mechanisms of action.<br /><br />The company’s lead program is THIO. The novel therapy “opens” the telomere cap of cancerous DNA, leading to rapid cell death.
